Home WakeSpace Scholarship › Electronic Theses and Dissertations

Studies of the efficacy of Ribonucleotide Reductase inhibition in preclinical models of Acute Myeloid Leukemia in combination with standard and novel therapeutics

Electronic Theses and Dissertations

Item Files

Item Details

abstract
Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options.
subject
Acute Myeloid Leukemia
Azacitidine
Decitabine
Didox
Preclinical
Ribonucleotide Reductase
contributor
Cook, Guerry (author)
Pardee, Timothy S (committee chair)
Seals, Darren (committee member)
Gmeiner, William (committee member)
Wadas, Thaddeus (committee member)
date
2015-06-23T08:35:49Z (accessioned)
2015-12-22T09:30:10Z (available)
2015 (issued)
degree
Cancer Biology (discipline)
embargo
2015-12-22 (terms)
identifier
http://hdl.handle.net/10339/57136 (uri)
language
en (iso)
publisher
Wake Forest University
title
Studies of the efficacy of Ribonucleotide Reductase inhibition in preclinical models of Acute Myeloid Leukemia in combination with standard and novel therapeutics
type
Dissertation

Usage Statistics